Long-Term Protection Elicited by a DNA Vaccine Candidate Expressing the prM-E Antigen of Dengue Virus Serotype 3 in Mice

被引:9
作者
Feng, Kaihao [1 ]
Zheng, Xiaoyan [2 ]
Wang, Ran [1 ]
Gao, Na [1 ]
Fan, Dongying [1 ]
Sheng, Ziyang [1 ]
Zhou, Hongning [3 ]
Chen, Hui [1 ]
An, Jing [1 ,4 ]
机构
[1] Capital Med Univ, Sch Basic Med Sci, Dept Microbiol & Parasitol, Beijing, Peoples R China
[2] Capital Med Univ, Beijing Friendship Hosp, Beijing Trop Med Res Inst, Beijing, Peoples R China
[3] Yunnan Inst Parasit Dis, Yunnan Prov Key Lab Vector Borne Dis Control & Re, Puer, Peoples R China
[4] Beijing Inst Brain Disorders, Ctr Epilepsy, Beijing, Peoples R China
来源
FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY | 2020年 / 10卷
基金
中国国家自然科学基金;
关键词
dengue virus; DNA vaccine; prM-E; immunization; cross-protection; T-CELLS; IMMUNE-RESPONSES; ENVELOPE; SAFETY; IMMUNOGENICITY; IMMUNIZATION; CONSENSUS; EPITOPES; CHILDREN; ADULTS;
D O I
10.3389/fcimb.2020.00087
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Dengue virus (DENV) is the causative agent of dengue, and its incidence has increased 30-fold in the past five decades. Among the four cocirculating serotypes, DENV3 is associated with an increased number of severe infections and has become widespread. Vaccination is the mainstay of prevention in reducing disease burden. Previously, the protective efficacy of DNA vaccine candidates toward DENV1, 2, and 4 was confirmed in mice. In this study, a DNA vaccine candidate (pVAX1-D3ME) expressing the prM and E proteins of DENV3 was constructed, and then the immunogenicity and protection were assessed in mice to further develop a tetravalent dengue vaccine. Moreover, the cross-reactive immune responses against the other three serotypes were investigated. The results showed that three doses of 50 mu g of pVAX1-D3ME were sufficient to induce strong antigen-specific T cell responses and robust and consistent neutralizing antibodies. Additionally, immunization with pVAX1-D3ME offered protective immunity against not only DENV3 but also the other three serotypes, which could be observed even after 12 months. This study shows great promise for the further evaluation of a dengue tetravalent DNA vaccine candidate in large animal models, including non-human primates.
引用
收藏
页数:12
相关论文
共 53 条
  • [1] New vaccines for neglected parasitic diseases and dengue
    Beaumier, Coreen M.
    Gillespie, Portia M.
    Hotez, Peter J.
    Bottazzi, Maria Elena
    [J]. TRANSLATIONAL RESEARCH, 2013, 162 (03) : 144 - 155
  • [2] The global distribution and burden of dengue
    Bhatt, Samir
    Gething, Peter W.
    Brady, Oliver J.
    Messina, Jane P.
    Farlow, Andrew W.
    Moyes, Catherine L.
    Drake, John M.
    Brownstein, John S.
    Hoen, Anne G.
    Sankoh, Osman
    Myers, Monica F.
    George, Dylan B.
    Jaenisch, Thomas
    Wint, G. R. William
    Simmons, Cameron P.
    Scott, Thomas W.
    Farrar, Jeremy J.
    Hay, Simon I.
    [J]. NATURE, 2013, 496 (7446) : 504 - 507
  • [3] Efficacy of a Tetravalent Dengue Vaccine in Healthy Children and Adolescents
    Biswal, Shibadas
    Reynales, Humberto
    Saez-Llorens, Xavier
    Lopez, Pio
    Borja-Tabora, Charissa
    Kosalaraksa, Pope
    Sirivichayakul, Chukiat
    Watanaveeradej, Veerachai
    Rivera, Luis
    Espinoza, Felix
    Fernando, LakKumar
    Dietze, Reynaldo
    Luz, Kleber
    da Cunha, Rivaldo Venancio
    Jimeno, Jose
    Lopez-Medina, Eduardo
    Borkowski, Astrid
    Brose, Manja
    Rauscher, Martina
    LeFevre, Inge
    Bizjajeva, Svetlana
    Bravo, Lulu
    Wallace, Derek
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (21) : 2009 - 2019
  • [4] Decreased accumulation of subgenomic RNA in human cells infected with vaccine candidate DEN4Δ30 increases viral susceptibility to type I interferon
    Bustos-Arriaga, Jose
    Gromowski, Gregory D.
    Tsetsarkin, Konstantin A.
    Firestone, Cai-Yen
    Castro-Jimenez, Tannya
    Pletnev, Alexander G.
    Cedillo-Barron, Leticia
    Whitehead, Stephen S.
    [J]. VACCINE, 2018, 36 (24) : 3460 - 3467
  • [5] Enhanced immune responses to E2 protein and DNA formulated with ISA 61 VG administered as a DNA prime-protein boost regimen against bovine viral diarrhea virus
    Cai, Dongjie
    Song, Quanjiang
    Duan, Cong
    Wang, Shenghua
    Wang, Jiufeng
    Zhu, Yaohong
    [J]. VACCINE, 2018, 36 (37) : 5591 - 5599
  • [6] Antibody response to dengue virus
    Cedillo-Barron, Leticia
    Garcia-Cordero, Julio
    Bustos-Arriaga, Jose
    Leon-Juarez, Moises
    Gutierrez-Castaneda, Benito
    [J]. MICROBES AND INFECTION, 2014, 16 (09) : 711 - 720
  • [7] A Human PrM Antibody That Recognizes a Novel Cryptic Epitope on Dengue E Glycoprotein
    Chan, Annie Hoi Yi
    Tan, Hwee Cheng
    Chow, Angelia Yee
    Lim, Angeline Pei Chiew
    Lok, Shee Mei
    Moreland, Nicole J.
    Vasudevan, Subhash G.
    MacAry, Paul A.
    Ooi, Eng Eong
    Hanson, Brendon J.
    [J]. PLOS ONE, 2012, 7 (04):
  • [8] Immunization with electroporation enhances the protective effect of a DNA vaccine candidate expressing prME antigen against dengue virus serotype 2 infection
    Chen, Hui
    Zheng, Xiaoyan
    Wang, Ran
    Gao, Na
    Sheng, Ziyang
    Fan, Dongying
    Feng, Kaihao
    Liao, Xianzheng
    An, Jing
    [J]. CLINICAL IMMUNOLOGY, 2016, 171 : 41 - 49
  • [9] Recombinant lipidated dengue-3 envelope protein domain III stimulates broad immune responses in mice
    Chiang, Chen-Yi
    Liu, Shih-Jen
    Hsieh, Chun-Hsiang
    Chen, Mei-Yu
    Tsai, Jy-Ping
    Liu, Hsueh-Hung
    Chen, I. -Hua
    Chong, Pele
    Leng, Chih-Hsiang
    Chen, Hsin-Wei
    [J]. VACCINE, 2016, 34 (08) : 1054 - 1061
  • [10] Identification of Cytotoxic T Lymphocyte Epitopes in Dengue Virus Serotype 1
    Duan, Zhiliang
    Guo, Jianglong
    Huang, Xi
    Liu, Huifang
    Chen, Xinyu
    Jiang, Minghua
    Wen, Jinsheng
    [J]. JOURNAL OF MEDICAL VIROLOGY, 2015, 87 (07) : 1077 - 1089